Loading
A phase 3 trial of Adagloxad simolenin run by OBI Pharma, Inc, active.
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC is a phase 3 interventional study registered as NCT03562637 by OBI Pharma, Inc, with 575 participants enrolled, started 2018-12-05. Conditions listed: Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Triple-negative breast cancer (TNBC).
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Early triple-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/